Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Aspira Women’s Health reported 3Q23 financial results, mostly in line with our estimates.</li><li>Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.</li><li>Our estimates for 2023 and 2024 remain in line with our prior estimates.</li></ul>

Aspira Women’s Health reported 3Q23 financial results, mostly in line with our estimates.Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.Our estimates for 2023 and 2024 remain in line with our prior estimates.

Aspira Women's Health, Inc. - Reports 3Q23 Results

<ul><li>On October 25, Aspira Women’s Health announced that a poster on its in-development miRNA-based ovarian cancer test was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer.</li><li>The poster, titled, “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.</li><li>The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even further when using a combination of approaches, including miRNA, proteins, and metadata. </li></ul>

On October 25, Aspira Women’s Health announced that a poster on its in-development miRNA-based ovarian cancer test was presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer.The poster, titled, “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even further when using a combination of approaches, including miRNA, proteins, and metadata. 

Aspira Women's Health, Inc. - Two Important Announcements from Aspira Women's Health

<ul><li>Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer.</li><li>Dr. Ryan Phan, who stepped down from the position, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs.</li><li>Dr. Berry is a recognized international expert in immunoassay development, antibody technology, and infectious diseases.</li></ul>

Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer.Dr. Ryan Phan, who stepped down from the position, remains as an advisor through the end of the year to help with the transition and provide scientific and operational advice related to ongoing product development programs.Dr. Berry is a recognized international expert in immunoassay development, antibody technology, and infectious diseases.

Aspira Women's Health, Inc. - Announces New Chief Scientific Officer

<div><div><div><div><ul style="list-style-type: disc;"><li><p>Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms.</p></li><li><p>This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis.</p></li><li><p>Verifying the test. This involves taking a test and comparing known samples to run against the test, verifying the test actually works. </p></li></ul></div></div></div></div>

Agreement with University of Oxford. On August 31, 2023, Aspira Women’s Health announced that it has entered into a material transfer agreement with the University of Oxford for the procurement of serum samples to be used to verify and validate AWH’s endometriosis blood testing algorithms.This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis.Verifying the test. This involves taking a test and comparing known samples to run against the test, verifying the test actually works. 

Aspira Women's Health, Inc. - Signs Exclusive Agreement with University of Oxford

<div><div><div><div><ul style="list-style-type: disc;"><li><p>Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.</p></li><li><p>EPS for the quarter was ($0.28), above our estimate of ($0.66).</p></li><li><p>AWH continues its good expense control, showing its ability to continue to grow revenue and test volumes, while keeping expenses well under control.</p></li></ul></div></div></div></div>

Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.EPS for the quarter was ($0.28), above our estimate of ($0.66).AWH continues its good expense control, showing its ability to continue to grow revenue and test volumes, while keeping expenses well under control.

Aspira Women's Health, Inc. - Reports In-Line 2Q23

United States

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company produces differentiated drugs that helps patients suffering from cancer, severe asthma, anemia, and other medical conditions. Pieris Pharmaceuticals serves customers worldwide.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Calyxt, Inc. provides agricultural biotechnology services. The Company researches and develops seeds and food ingredients for agricultural, feed, and food applications, as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt markets its products in the United States.

Evelo Biosciences, Inc. operates as a bio-technology company. The Company develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases. Evelo Biosciences serves customers in the State of Massachusetts.

UNITY Biotechnology, Inc. operates as a biotechnology company. The Company develops therapeutics that prevents, halts, and reverses osteoarthritis, ophthalmology, and pulmonary diseases. UNITY Biotechnology serves the health care sectors in the United States.

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Biotron Limited specializes in the funding, management and commercialization of biomedical projects that result from research conducted at the John Curtin School of Medical Research, a research institute within the Australian National University.  The Group conducts diagnostic and therapeutic research with the intention of creating compounds and diagnostics that can be sold or licensed.

Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

Daesung Microbiological Labs Co., Ltd. develops and manufactures canine, poultry, swine, and bovine drugs and vaccines.  The Company's products have applications for increasing immunity and preventing epidemic for livestock. Daesung Microbiological Labs also researches microorganism for ocean and soil improvement purposes.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

Ribomic, Inc. develops ribonucleic acids (RNA) called aptamers. The company conduct research and develops new medication based on Ribomic Aptamer Refined Th erapeutics System. The company also conduct advisory to pharmaceutical companies and product licensing.

Prescient Therapeutics Limited is an oncology company. The Company researches, develop, and commercializes novel cancer treatments treatments. Prescient Therapeutics treats myeloma, breast, and pancreatic cancer.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Vectorite Biotech Inc. is a biomedical company focused on the research and development of adult healthy cells and cell formulation, medical technologies and product development of targeted immune cell therapy treatment to treat disease and improve the patients' quality of life.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aspira Women's Health (AWH US)

Aspira Women's Health, Inc. - Reports 3Q23 Results

Revenue of $2.2 million was below our estimate, but good expense control is in place and is expected to continue.Our estimates for 2023 and 2024...

Water Tower Research

Aspira Women's Health, Inc. - Two Important Announcements from Aspira Women's Health

The study showed that the addition of miRNA improved the detection of early-stage ovarian cancers and that diagnostic performance improved even...

Water Tower Research

Aspira Women's Health, Inc. - Announces New Chief Scientific Officer

Aspira Women’s Health announced it has named Jody Berry, Ph.D as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down from the...

Water Tower Research

Aspira Women's Health, Inc. - Signs Exclusive Agreement with University of Oxford

This means that AWH will be able to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis...

Water Tower Research

Aspira Women's Health, Inc. - Reports In-Line 2Q23

Aspira Women’s Health reported in-line 2Q23 financial results. Revenues in the quarter were $2.5 million, below our estimate of $3.2 million.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)